Labrador Gold Corp (LAB) Fair Value & Analysis
Healthcare · CA · Market cap 45.3M ZAC
Fair value as of: Jun 26, 2026
From 15 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from R0.8700 to R0.4600 (−47.1%) since Jun 24, 2026. Share price +66.7% over the past month.
Price vs Fair Value (12 months)
12‑month range R0.0200 – R0.0900 · fair‑value band R0.2950 – R0.6450 · the R0.0500 price screens below the R0.4600 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Labrador Gold Corp (LAB) currently trades at R0.0500, while our model-based Fair Value estimate is R0.4600 — implying the stock looks roughly 820.0% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Labrador Gold Corp generated revenue of 317M ZAR at a net margin of 48.8%. It earns a return on equity of 128.0%. Net debt stands at 36.6M ZAR. The stock trades on a trailing P/E of 0.2. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Labrador Gold Corp. engages in the acquisition and exploration of gold properties in the Americas. It explores for gold, copper, and silver deposits. The company owns 100% interest in the Borden Lake property located in Chapleau, Ontario; and the Scotch property located in Moncton, New Brunswick. In addition, it holds 100% interest in the Kingsway property located near Gander, Newfoundland; and the Hopedale property located in Florence Lake greenstone belt. Labrador Gold Corp. was formerly known as Nikos Explorations Ltd. and changed its name to Labrador Gold Corp. in December 2017. The company was incorporated in 1987 and is headquartered in Toronto, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Labrador Gold Corp reported revenue of R199M in FY2025 versus R29.3M in FY2021, a compound +61.6%/yr. Reported net income was R118M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Labrador Gold Corp (LAB) undervalued?
What is the fair value of LAB?
What is the quality score of LAB?
What is the revenue of Labrador Gold Corp (LAB)?
What is the net profit margin of LAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.